Is it time to seriously target obesity to prevent and control diabetes?

Canadian Journal of Diabetes

Volumn 35, Issue 2, 2011, Pages 129-135

  Sharma, Arya M ^a   Padwal, Raj ^a   Karmali, Shahzeer ^a   Birch, Daniel W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bariatric surgery; Cost effectiveness; Obesity; Type 2 diabetes

Indexed keywords

GHRELIN; GLUCAGON LIKE PEPTIDE 1; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; BODY MASS; CANADA; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EPIDEMIC; GASTRIC BANDING; GLYCEMIC CONTROL; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HORMONE RELEASE; HUMAN; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK REDUCTION; SLEEVE GASTRECTOMY; WEIGHT REDUCTION;

EID: 79958041870     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-2671(11)52010-6     Document Type: Review

References (44)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27:1047-1053.
3. Ohinmaa A, Jacobs P, Simpson S, et al. The projection of prevalence and cost of diabetes in Canada: 2000 to 2016. Can J Diabetes. 2004;28:116-123.
4. Canadian Diabetes Association. The prevalence and costs of diabetes. http://www.diabetes.ca/documents/about-diabetes/PrevalanceandCost_09.pdf. Accessed March 28, 2011.
5. World Health Organization. Obesity and overweight. Fact Sheet No. 311. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed March 28, 2011.
6. Statistics Canada. Canadian health measures survey. The Daily. January 13, 2010. http://www.statcan.gc.ca/daily-quotidien/100113/dq100113-eng.pdf. Accessed March 28, 2011.
7. Padwal RS, Sharma AM. Treating severe obesity: morbid weights and morbid waits. CMAJ. 2009;181:777-778.
8. Tuomilehto J. Counterpoint: evidence-based prevention of type 2 diabetes: the power of lifestyle management. Diabetes Care. 2007;30:435-438.
9. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ.2007;334:299.
10. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679.
11. Simmons RK, Harding AH, Jakes RW, et al. How much might achievement of diabetes prevention behaviour goals reduce the incidence of diabetes if implemented at the population level? Diabetologia.2006;49:905-911.
12. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566-1575.
13. Sassi F, Cecchini M, Lauer J, et al. Improving lifestyles, tackling obesity: the health and economic impact of preventive strategies. OECD Health Working Papers, No. 48. Paris, France: OECD; 2009.
14. McPherson K, Marsh T, Brown M. Foresight: Tackling Obesities: Future Choices - Modelling Future Trends in Obesity & Their Impact on Health. 2nd ed. London, UK: Government Office for Science; 2009. http://www.bis.gov.uk/assets/bispartners/foresight/docs/obesity/14.pdf. Accessed March 28, 2011.
15. Svetkey LP, Stevens VJ, Brantley PJ, et al; Weight Loss Maintenance Collaborative Research Group. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA. 2008;299:1139-1148.
16. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet.1998;352:167-172.
17. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119-2125.
18. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706-1713.
19. Astrup A, Rossner S, Van Gaal L, et al; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study. Lancet. 2009;374:1606-1616.
20. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring). 2006;14:1283-1293.
21. Sjostrom L, Narbro K, Sjostrom CD, et al; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
22. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-761.
23. Ditschuneit HH. Do meal replacement drinks have a role in diabetes management? Nestle Nutr Workshop Ser Clin Perform Programme. 2006; 11:171-179.
24. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321-1326.
25. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-1672.
26. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003;26:125-131.
27. James WP, Caterson ID, Coutinho W, et al; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-917.
28. Boekholdt SM, Peters RJ. Rimonabant: obituary for a wonder drug. Lancet. 2010;376:489-490.
29. Sjostrom L, Lindroos AK, Peltonen M, et al; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.
30. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.
31. Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6:707-713.
32. Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28:2406-2411.
33. Rubino F, Kaplan LM, Schauer PR, et al; Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399-405.
34. Klarenbach S, Padwal R, Wiebe N, et al. Bariatric surgery for severe obesity: systematic review and economic evaluation. Technology Report No. 129. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2010. http://www.cadth.ca/media/pdf/H0485_Bariatric_Surgery_for_Severe_Obesity_tr_e.pdf. Accessed March 28, 2011.
35. Makary MA, Clarke JM, Shore AD, et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg. 2010;145:726-731.
36. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
37. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ. 2009;180:400-407.
38. Cobourn C, Mumford D, Chapman MA, et al. Laparoscopic gastric banding is safe in outpatient surgical centers. Obes Surg. 2010;20:415-422.
39. Birkmeyer NJ, Dimick JB, Share D, et al; Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Michigan. JAMA. 2010;304:435-442.
40. Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care. 2005;28:481-484.
41. Courcoulas AP, Flum DR. Filling the gaps in bariatric surgical research. JAMA. 2005;294:1957-1960.
42. Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med.2010;61:393-411.
43. Rubino F, R'bibo SL, del Genio F, Mazumdar M, McGraw TE. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol. 2010;6:102-109.
44. Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity (Silver Spring). 2009;17:941-964.